ライフサイエンスコーパス: biosafety

1 holerae vaccine strains should enhance their biosafety.

2 to address questions regarding logistics and biosafety.

3 ve oxygen species (ROS) yield, and excellent biosafety.

4 ing increasingly important to regulation and biosafety.

5 of tumors in vivo with superior efficacy and biosafety.

6 argeting, prolonged retention, and excellent biosafety.

7 stry) of these nanomaterials influence their biosafety.

8 w shear and immune clearance, with excellent biosafety.

9 the potentially released Mn(2+) for enhanced biosafety.

10 afety practices and improve their culture of biosafety.

11 ting with high purity, biocompatibility, and biosafety.

12 rity (hereafter collectively referred to as 'biosafety') a popular and timely topic globally.

13 Biosafety analysis was performed and showed an acceptabl

14 ies of CRISPR-based biosensors in pathogenic biosafety analysis.

15 hi) research to provide an evidence base for biosafety and biocontainment.

16 problems involved in this epidemic have made biosafety and biosecurity (hereafter collectively referr

17 ss commercialisation and scaling challenges, biosafety and biosecurity considerations including bioco

18 In the United States (US), biosafety and biosecurity oversight of research on virus

19 s a select agent, is considered to pose both biosafety and biosecurity threats.

20 including food safety, clinical diagnostics, biosafety and biosecurity.

21 kinetics is very important to understand QD biosafety and cytotoxicity.

22 These initial biosafety and efficacy data support further development

23 on these insights is critical for enhancing biosafety and ensuring effective pathogen eradication.

24 of-care in vitro diagnostics, food analysis, biosafety and environmental monitoring, forensics, and s

25 he high throughput and rapid food detection, biosafety and environmental monitoring.

26 ory elements are likely to improve intrinsic biosafety and may be particularly useful for a number of

27 In light of concerns about biosafety and potential germ line transmission, they hav

28 It provides a general overview of the biosafety and regulation of genetically modified plants

29 alternative transport system to address the biosafety and stability challenges associated with expan

30 Biosafety and uptake efficiency of the EMs were evaluate

31 to model deployment so as to allow potential biosafety and/or biosecurity measures.

32 apid blood clearance, low background signal, biosafety, and acceptable radiation dosimetry in humans.

33 ing of biosafety practices, vigilance toward biosafety, and enforcement of biosafety practices throug

34 e to animal studies, information technology, biosafety, and human resources.

35 of training, uncertainty about occupational biosafety, and lack of adaptation of services to tend to

36 need for specialized equipment, prioritizes biosafety, and utilizes cost-effective reagents.

37 A risk-based biosafety approach for in vitro and in vivo culture of O

38 g been considered as the "gold standard" for biosafety assessments of chemicals and pollutants due to

39 (-1) day(-1) in rainbow trout and assess its biosafety at concentration of 80, 240, 400, and 800 mg k

40 tilize surrogates of infection that increase biosafety but reduce biological relevance.

41 es; engineering controls (e.g., clean rooms, biosafety cabinets) as needed; and homogeneous matrix-ba

42 n the Chinese Ministry of Agriculture issued biosafety certificates for commercial production of two

43 entional decontamination, posing significant biosafety challenges in the medical and research environ

44 mplete autopsies are seldom performed due to biosafety challenges, especially in low-resource setting

45 ountermeasures are restricted by the current biosafety classification of EBOVs.

46 on the basis of two GMO databases, i.e. the Biosafety Clearing-House and the EUginius database.

47 a biosafety level 2 (BSL-2) agent by the NIH biosafety committee.

48 There are biosafety concerns about reintroduction of the disease f

49 ited by unfavorable drug-like properties and biosafety concerns arising from nonspecific biodistribut

50 y nirmatrelvir-resistant mutants without the biosafety concerns associated with gain-of-function (GoF

51 reintroduction of the disease, but there are biosafety concerns for both OPV and IPV.

52 pabilities pose the greatest biosecurity and biosafety concerns is necessary in order to establish ta

53 of transgene silencing and the toxicity and biosafety concerns of working with viral vectors.

54 of transgene silencing, and the toxicity and biosafety concerns of working with viral vectors.

55 of transgene silencing, and the toxicity and biosafety concerns of working with viral vectors.

56 cold chain to centralized laboratories, and biosafety concerns surrounding specimen handling have li

57 Such an approach minimizes biosafety concerns that could apply to single, replicati

58 its application has been linked to numerous biosafety concerns, originated from UV phototoxicity.

59 , depend on sample availability, and present biosafety concerns, so reliable methods for sequence-bas

60 nt larger-capacity viral vectors suffer from biosafety concerns, whereas plasmid-based approaches hav

61 secondary environmental contamination and/or biosafety concerns.

62 ned awareness of potential misuse related to biosafety concerns.

63 is therefore highly desirable for addressing biosafety concerns.

64 sible light instead of UV and bypasses those biosafety concerns; however, the crosslinking system nee

65 dy of aspects of CCHFV biology under relaxed biosafety conditions.

66 Additionally, we discuss the biosafety considerations and potential applications of g

67 Due to biosafety considerations the standard testing process re

68 e experiments to be performed under standard biosafety considerations.

69 hat control and limit Mycoplasma growth, for biosafety containment applications.

70 t, and screening of antiviral drugs in a low biosafety containment environment.

71 ctable viral outbreak requiring high/maximum biosafety containment facilities (i.e. BSL3 and BSL4), X

72 (MALDI) mass spectrometry imaging suite in a biosafety containment facility, we show that the key ste

73 screening of small-molecule libraries under biosafety containment level 2 (BSL2) conditions.

74 nairoviruses without the need for high-level biosafety containment, as is required for CCHFV.

75 tibody (nAb) assays often require high-level biosafety containment, sophisticated instrumentation, an

76 ing in a sealed glove box, offering complete biosafety containment.

77 s of SARS-CoV-2 mediated entry under reduced biosafety containment.

78 The Environmental Biosafety Criterion (EBC) was defined as the absence of

79 atabases, however, are actually designed for biosafety determination.

80 These results showed an excellent systemic biosafety determined by histological analysis and liver/

81 rious opposition regarding issues of policy, biosafety, effectiveness, and reversal.

82 de the first non-glucagon-like peptide (GLP) biosafety, efficacy, biodistribution, shedding, and hist

83 1, 2, or 3 status did not possess all of the biosafety elements considered minimally standard for the

84 logy of highly pathogenic viruses in a lower biosafety environment.

85 of-care in vitro diagnostics, food analysis, biosafety, environmental applications, etc.

86 omising field with potential applications in biosafety, environmental monitoring, and personalized me

87 lectrolyte decomposition at high voltage and biosafety/environmental concerns when electrolyte leakag

88 ssembling life-like modules while addressing biosafety, equity, and ethical concerns in order to guid

89 Biosafety evaluation showed effective feed consumption,

90 biomacromolecules and their in vitro/in vivo biosafety evaluations.

91 duration of 5 days, while the assessment of biosafety extended for a 30-day safety margin, followed

92 ord and a Royal Society Wolfson grant funded biosafety facility.

93 ntaining the additional Phe-metabolizing and biosafety features found in SYNB1618.

94 ome to provide lentivirus vectors with novel biosafety features.

95 These biosafety hurdles could be overcome by the use of recomb

96 MTAs show excellent therapeutic efficacy and biosafety in 4 T1 xenograft mouse models.

97 is a need to establish a protocol to ensure biosafety in clinical practice during the current COVID-

98 gical cells and desirable biodegradation and biosafety in physiological environments.

99 pecifically target the kidney while ensuring biosafety in their future clinical translation.

100 s, we confirmed that IgG78-DM1 had qualified biosafety in vivo.

101 over, RBC-ND shows good biocompatibility and biosafety in vivo.

102 ratories, rather than the few with extensive biosafety infrastructure.

103 Intensive physical distancing and biosafety interventions prove cost-effective.

104 Pathogenic biosafety is a worldwide concern.

105 However, their biosafety is of major concern.

106 ement lysis test, the trypanolysis test, but biosafety issues and technological requirements prevent

107 challenges and discuss the environmental and biosafety issues involved in the use of this technology

108 ent reporting, and risk management to reduce biosafety lapses and ensure long-term laboratory operati

109 re volumes) be performed in high-containment biosafety level (BSL) 3 laboratories.

110 athogens in existence, requiring the highest biosafety level (BSL) containment (BSL4).

111 se of humans caused by CCHF virus (CCHFV), a biosafety level (BSL)-4 pathogen.

112 high-titer convalescent plasma products in a biosafety level 1 environment.

113 aled that subsets of laboratories that claim biosafety level 1, 2, or 3 status did not possess all of

114 red cells and animals and is classified as a biosafety level 2 (BSL-2) agent by the NIH biosafety com

115 Here, we exploit a biosafety level 2 (BSL-2) chimeric Sindbis virus system

116 cycle, but it still can be carried out under biosafety level 2 (BSL-2) conditions.

117 st highly pathogenic influenza viruses under biosafety level 2 (BSL-2) conditions.

118 from the select-agent rule and handled at a biosafety level 2 (BSL2) laboratory.

119 ophila melanogaster, in conjunction with the biosafety level 2 (BSL2) Nine Mile phase II (NMII) clone

120 iral drug screening in human cell culture at biosafety level 2 (BSL2) with high-throughput compatible

121 iral drug screening in human cell culture at biosafety level 2 (BSL2) with high-throughput compatible

122 We modified a biosafety level 2 chimeric virus system to facilitate ev

123 ate 7a functions during CoV infections under biosafety level 2 conditions, we constructed recombinant

124 nt reporters, which can be safely used under biosafety level 2 conditions.

125 that allow experiments to be performed under biosafety level 2 conditions.

126 lated orthonairovirus that can be handled in biosafety level 2 containment and has been proposed as a

127 man immunodeficiency virus (HIV) type 1 in a biosafety level 2 containment facility, without any appa

128 ral gene, allowing it to be manipulated in a biosafety level 2 environment.

129 can be performed with lower biocontainment (Biosafety Level 2 facilities) and allows for further inc

130 t are amenable to high-throughput screens in biosafety level 2 laboratories.

131 e viruses or cells and can be performed in a biosafety level 2 laboratory within two hours.

132 ome replication system that can be used in a biosafety level 2 laboratory.

133 ganisms nonviable and safe for handling in a biosafety level 2 laboratory.

134 rus Pichinde virus (PICV) has been used as a biosafety level 2 model for the Lassa virus.

135 riants of the arenavirus Pichinde, used as a biosafety level 2 model of Lassa fever virus as it produ

136 therefore can be handled more facilely using biosafety level 2 practices.

137 ughput-imaging-based neutralization assay at biosafety level 2.

138 Under biosafety level 3 (agricultural) conditions, we have gen

139 ) genes during viral infection in mice under biosafety level 3 (agricultural) conditions.

140 The JHH BCU and The Johns Hopkins biosafety level 3 (BSL-3) clinical microbiology laborato

141 atency, work with B. pseudomallei requires a biosafety level 3 (BSL-3) containment facility.

142 (SARS-CoV-2) infection require operation in biosafety level 3 (BSL-3) containment.

143 (50%) of these ETC clinical laboratories had biosafety level 3 (BSL-3) containment.

144 and even basic studies must be conducted in biosafety level 3 (BSL-3) facilities.

145 In a biosafety level 3 (BSL-3) facility, cultures were infect

146 that research on the virus is restricted to biosafety level 3 (BSL-3) laboratories.

147 authentic SARS-CoV-2 has been restricted to biosafety level 3 (BSL-3) laboratories.

148 hly pathogenic H5N1 viruses is restricted to Biosafety Level 3 (BSL-3) laboratories.

149 l viral pathogens that need to be handled in biosafety level 3 (BSL-3) or higher facilities.

150 spiratory syndrome coronavirus (SARS-CoV), a biosafety level 3 (BSL-3) pathogen.

151 The biosafety level 3 (BSL-3) requirement to culture severe

152 n system that can be readily adopted without biosafety level 3 (BSL-3) restrictions.

153 RS-CoV-2) are currently permitted only under biosafety level 3 (BSL3) containment.

154 gistical challenges of handing SARS-CoV-2 in biosafety level 3 (BSL3) facilities.

155 iveness was assessed using cultured virus in biosafety level 3 and in saliva clinical samples compari

156 f SARS-CoV-2 requires it to be handled under biosafety level 3 conditions.

157 irus 2 (SARS-CoV-2) that can be done without biosafety level 3 containment and in multiple species ar

158 fection, where virus spread and the need for biosafety level 3 containment complicate the use of wild

159 rome coronavirus 2 antigens are present, but Biosafety Level 3 facilities are required.

160 y studied, partly because the virus requires biosafety level 3 facilities which can limit the scope o

161 was evaluated in a field test conducted in a Biosafety Level 3 facility, where the system was challen

162 esearch on SARS-CoV-2 has been restricted to biosafety level 3 laboratories.

163 lization assays and do not require access to biosafety level 3 laboratories.

164 requirement for conducting experiments in a biosafety level 3 laboratory (BSL-3) limit the ability t

165 s Brucella has been hindered by the need for biosafety level 3 select agent containment.

166 rapid testing of viral variants outside of a biosafety level 3 setting and demonstrate N mutations an

167 removing fixed M. tuberculosis samples from biosafety level 3.

168 est with a clinical isolate of SARS-CoV-2 at biosafety level 3.

169 ing multiple recombinants under constraining biosafety level 4 (BSL-4) conditions.

170 virus L polymerase protein and the need for biosafety level 4 (BSL-4) containment conditions for wor

171 enaviruses is hampered by the requirement of biosafety level 4 (BSL-4) facilities to work with these

172 Since handling of the virus requires a biosafety level 4 (BSL-4) facility, little is known abou

173 nus of paramyxoviruses, which are designated biosafety level 4 (BSL-4) organisms due to the high mort

174 eV) exhibit high lethality in humans and are biosafety level 4 (BSL-4) paramyxoviruses in the growing

175 The results demonstrate that the biosafety level 4 (BSL-4) suit protects workers from aer

176 ipah virus (NiV) and Hendra virus (HeV), are biosafety level 4 (BSL-4) zoonotic pathogens that cause

177 th infectious Ebola viruses is restricted to biosafety level 4 (BSL4) laboratories, presenting a sign

178 V), the causative agent of Lassa fever, is a biosafety level 4 (BSL4) pathogen that requires handling

179 For biosafety level 4 (BSL4) pathogens such as the deadly Ni

180 For biosafety level 4 (BSL4) pathogens such as the deadly Ni

181 These include the biosafety level 4 agents Hendra (HeV) and Nipah (NiV) vi

182 nsport in Marburg virus-infected cells under biosafety level 4 conditions.

183 o its high pathogenicity and requirement for biosafety level 4 containment.

184 rus entry, replication, and assembly without biosafety level 4 containment.

185 extraordinary pathogenicity, which requires biosafety level 4 containment.

186 ons, but for the Ebola virus, which requires biosafety level 4 facilities for experimentation, modell

187 been developed, the requirement for maximum biosafety level 4 facilities limits the development of c

188 nction with the development of sophisticated biosafety level 4 laboratories at the US Army Medical Re

189 Frozen samples were shipped to a reference biosafety level 4 laboratory for RNA viral load measurem

190 However, the biosafety level 4 NiV and HeV are highly pathogenic and

191 hibit Nipah virus (NiV), a highly pathogenic biosafety level 4 paramyxovirus.

192 tainment level 4 (CL4) laboratories studying biosafety level 4 viruses are under strict regulations t

193 EVD) reminds us of how little is known about biosafety level 4 viruses.

194 The work was performed at biosafety level 4 with wild-type virus with specificity

195 single-domain antibodies (sdAbs) selected at biosafety level 4.

196 desh strain (NiVB) infection in marmosets at biosafety level 4.

197 custom-built, 3.86 m wind tunnel housed in a biosafety level class II facility.

198 ficult to manipulate or those requiring high biosafety level containment.

199 ection in cultured cells which requires high biosafety level containment.

200 hly pathogenic paramyxovirus classified as a biosafety level four agent.

201 ited due to the use of live virus and strict biosafety level requirements necessary to perform a plaq

202 the virus can be handled only at the highest biosafety level, research is restricted to a few special

203 he irradiation protocol, using lentiviruses (biosafety level-2 agent) and establishment of the germic

204 candidate and a research tool for potential biosafety level-2 use.

205 e infectious SARS-CoV-2 must be handled in a biosafety level-3 laboratory.

206 ential biological weapon, is classified as a biosafety level-4 agent because of its high mortality ra

207 ovides a safe means to handle EBOV outside a biosafety level-4 facility and will stimulate critical s

208 hallenges investigating viruses that require biosafety-level 3 or 4 handling.

209 Overall, our work describes a biosafety-level-2 method to elucidate the mutational spa

210 deadly (~57%-59% fatality rate) and require biosafety-level-4 containment.

211 ells, introduce stem-cell-based toolkits for biosafety-level-4 virology, and explore the arterial tro

212 nic viruses to recapitulate entry at reduced biosafety levels.

213 dy the filovirus replication cycle under low biosafety levels.

214 ous cell culture assay for BASV and at lower biosafety levels.

215 n large pai-conjugated groups), exhibit poor biosafety, low QYs, and/or uncontrollable pharmacokineti

216 thogen research management within a standard biosafety management framework is recommended but is cha

217 ious virus) in tissues necessitates enhanced biosafety measures in healthcare and autopsy settings.

218 , a procedure that does not require advanced biosafety measures or a special autopsy room.

219 insic biocontainment would provide essential biosafety measures to secure these closed systems and en

220 es should be collected-and under which exact biosafety measures-are necessary to facilitate and expan

221 procedure-associated contagion, using basic biosafety measures.

222 r of the enhancement of therapy efficacy and biosafety of CO therapy.

223 Biosafety of GA@Ag-CuO nanocomposite was assessed toward

224 ere we present an approach to strengthen the biosafety of gain-of-function influenza experiments.

225 es to determine the experimental utility and biosafety of hESCs and (ii) optimization and standardiza

226 Significant progress was achieved in the biosafety of HIV-derived vectors by eliminating all the

227 ed hidden toxicity aspects, highlighting the biosafety of InP-based nanocrystals and outlining the im

228 in understanding of human health impacts and biosafety of mosquito genetic control tools, and continu

229 any applications as a tool for understanding biosafety of numerous other Cd-based QDs, including leac

230 The biosafety of the film was confirmed by the absence of sh

231 In a healthy murine model, the biosafety of the nanosuspension was confirmed.

232 While the actual biosafety of the vector will ultimately be proven in viv

233 and mandated to unequivocally establish the biosafety of this device and related bioartificial organ

234 system (BLSS), we proceeded to evaluate the biosafety of this device.

235 can inform coordinated efforts to strengthen biosafety oversight, incident reporting, and risk manage

236 rthohantaviruses and guide public health and biosafety policy.

237 nged Wisconsin laboratories to examine their biosafety practices and improve their culture of biosafe

238 importance of epidemiologic tracing, proper biosafety practices in the clinical diagnostic laborator

239 rtance of laboratorians strictly adhering to biosafety practices recommended for the handling of infe

240 gilance toward biosafety, and enforcement of biosafety practices throughout the laboratory setting.

241 ontinued microbiology-based understanding of biosafety practices, vigilance toward biosafety, and enf

242 iments and the prioritization of appropriate biosafety practices.

243 ies should be examined to ensure appropriate biosafety precautions.

244 tural environments, remains a major unsolved biosafety problem.

245 to remain vigilant in the use of appropriate biosafety procedures, particularly when working with unk

246 One constraint is optimisation of national biosafety processes to support rapid and safe uptake of

247 comparatively assessed for its efficacy and biosafety profile against R. solanacearum.

248 lentiviral platforms that offer an improved biosafety profile alongside greater efficiency for hemat

249 Finally, we further validated the biosafety profile and efficacy of platelet-CAR-T in a po

250 emonstrate that TA2-nHP66 exhibits excellent biosafety profile without apparent systemic toxicities.

251 sted that cell-permeable aKG displays a good biosafety profile, eliminates aspartate only in OXPHOS-i

252 ic effect in mammalian cells and have a good biosafety profile.

253 n of immune memory and exhibited a favorable biosafety profile.

254 clinical use, nanoparticles with established biosafety profiles should be used to decrease long-term

255 The cRGD-CPNPs also displayed good biosafety profiles, as inferred from PA tomography, bloo

256 tes tumor-specific lymphocytes with improved biosafety profiles.

257 with HIV or viral hepatitis, despite modern biosafety protocols and decades of scientific progress.

258 ll mass spectrometry) method compatible with biosafety protocols, to acquire metabolomics data from i

259 w methods that are specifically tailored for biosafety purposes.

260 implementation are also discussed, including biosafety, quality control, and proficiency testing stra

261 With the caveat that biosafety regulations preclude testing of a complemented

262 Although biosafety regulations precluded our testing the compleme

263 Although biosafety regulations precluded our testing the compleme

264 imited availability of diagnostic assays and biosafety regulations required for handling infectious C

265 transgene-free crop improvement while easing biosafety regulations.

266 at farmer's field level after fulfilling the biosafety requirements to boost the sugarcane production

267 use of such agents complies with appropriate biosafety requirements.

268 due to logistical challenges, high costs and biosafety requirements.

269 l infection control protocols may complement biosafety requirements.

270 ies in compliance of both animal welfare and biosafety requirements.

271 ent meeting of the International Society for Biosafety Research (ISBR) focused on so-called genetical

272 Biosafety research covers a broad and diverse range of t

273 However, the data-driven literature on biosafety research discovery is quite scant.

274 algorithm (LDAPR) to extract knowledge from biosafety research publications from 2011 to 2020.

275 t to quickly identify hotspots and trends in biosafety research through big data analysis.

276 To circumvent biosafety restrictions associated with the use of live L

277 yclable but infrequently recycled because of biosafety restrictions.

278 less contributory to a microbiology-focused biosafety risk assessment than information on the specim

279 a questionnaire-based, microbiology-focused biosafety risk assessment.

280 ack viral nucleic acids, thus mitigating the biosafety risks of conventional assays.

281 thogen escapes from laboratory settings pose biosafety risks, affecting laboratory personnel, the sci

282 ive additives into the body, which may cause biosafety risks.

283 s 'safe' to operate, but much less so in the biosafety sector.

284 poration technique not only maintains robust biosafety standards but also enables the continuous capt

285 ay a foundation to develop viable and robust biosafety systems to exploit a synthetic Mycoplasma chas

286 Tools for analyzing pathogenic biosafety, that are precise, rapid and field-deployable,

287 ate ultrasound-driven implants for long-term biosafety therapy in deep brain stimulation through an e

288 tumor volume reduction (45 %) with improved biosafety, thereby demonstrating the clinical potential

289 n open science practices and biosecurity and biosafety to identify risks and opportunities for risk m

290 Our findings have implications for biosafety, vector design, and cell biology research.

291 Using a model system to ensure biosafety, we show that a small increase in body tempera